Loading
Life sciences · Journal article
Macromolecular Rapid Communications · September 19, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Triple‐negative breast cancer (TNBC) is a highly aggressive and lethal malignancy with poor response to conventional therapeutic regimens. Thus, there is an urgent need to develop precision theranostic nanoplatforms that integrate accurate imaging guidance with synergistic therapeutic modalities. Herein, a novel responsive multifunctional Ag 2 S/MnO 2 @SiO 2 (AMS) nanofactory was constructed for NIR‐II fluorescence/photoacoustic (NIR‐II FL/PA) imaging‐guided synergistic chemodynamic/photothermal therapy (CDT/PTT) of TNBC. Leveraging the unique biochemical cues of the TME, AMS undergoes efficient degradation, leading to the rapid release of Ag 2 S and Mn 2+ ions. The released Ag 2 S enables precise tumor localization via NIR‐II FL/PA imaging, while simultaneously mediating efficient PTT upon 808 nm laser irradiation. Meanwhile, Mn 2+ ions exhibit Fenton‐like catalytic activity to convert endogenous H 2 O 2 into highly toxic • OH for CDT, and the hyperthermia induced by PTT further accelerates the Fenton‐like reaction to boost CDT efficacy, thus achieving highly efficient synergistic antitumor therapy. Collectively, the AMS nanofactory with favorable biocompatibility provides a promising strategy for precision theranostics of TNBC.